 Glucagon-Like Peptides
"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 2 | 3 | | 2024 | 7 | 3 | 10 | | 2025 | 11 | 1 | 12 | | 2026 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR, Ackeifi CA, Rosen J, Pyle L, Snell-Bergeon JK, Shah VN. Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care. 2026 May 01; 49(5):718-723.
-
Busti M, Canonico ME, Keramida K, Palazzuoli A, Kato E, Sakata Y, Alexy T, Grupper A, Nodari S, Ojji DB, Sverdlov AL, Guimaraes PO, Musella F, Ambrosy AP, Girerd N, Monzo L. Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie. Heart Fail Rev. 2026 Apr 15; 31(1).
-
Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, Brown TT, Fichtenbaum CJ, Heath SL, Sattler FR, Lake JE. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clin Infect Dis. 2026 Mar 17; 82(3):e544-e548.
-
Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
-
Chao AM, Gilden A, Wadden TA. Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. PLoS Med. 2026 Jan; 23(1):e1004871.
-
Lehenbauer KS, Nelson AJ, Nodari S, Sverdlov AL, Harrington J. The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial. Heart Fail Rev. 2025 Dec 10; 31(1):11.
-
McGinnis T, McCallum M, Pan Z, Cunningham C, Saxon DR, Thomas E. Clinical Effectiveness of Semaglutide for Weight Loss in a Veterans Affairs' Anti-Obesity Pharmacotherapy Clinic. J Gen Intern Med. 2026 05; 41(6):1547-1555.
-
Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 Jan; 109(1):6-16.
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
-
Derington CG, Sarwal A, Wei G, Hartsell SE, Throolin M, Singh R, Nevers MR, Zhang C, Katkam N, Takyi A, Chakravartula AR, Babu P, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Shen J, Beddhu S. Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Netw Open. 2025 Oct 01; 8(10):e2537297.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|